Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.

Jensen CD, Steval A, Partington PF, Reed MR, Muller SD.

J Bone Joint Surg Br. 2011 Jan;93(1):91-5. doi: 10.1302/0301-620X.93B1.24987.

PMID:
21196550
2.

A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.

Chahal GS, Saithna A, Brewster M, Gilbody J, Lever S, Khan WS, Foguet P.

Ortop Traumatol Rehabil. 2013 Mar-Apr;15(2):125-9. doi: 10.5604/15093492.1045953.

PMID:
23652532
3.

Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S.

Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.

PMID:
23197272
4.

Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.

Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD.

J Bone Joint Surg Am. 2012 Sep 5;94(17):1554-8.

PMID:
22832942
5.

Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.

Lazo-Langner A, Fleet JL, McArthur E, Garg AX.

J Thromb Haemost. 2014 Oct;12(10):1626-35. doi: 10.1111/jth.12675. Epub 2014 Aug 26.

6.

Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG.

Thromb Haemost. 2007 Jun;97(6):931-7.

PMID:
17549294
7.

Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.

Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R.

Eur J Orthop Surg Traumatol. 2013 May;23(4):481-6. doi: 10.1007/s00590-012-0987-y. Epub 2012 Apr 17.

PMID:
23412293
8.

The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement.

Rath NK, Goodson MW, White SP, Forster MC.

Knee. 2013 Dec;20(6):397-400. doi: 10.1016/j.knee.2013.01.006. Epub 2013 Apr 6.

PMID:
23566737
9.

Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):151-3.

PMID:
19743567
10.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators.

Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24.

PMID:
18582928
11.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

12.
13.

Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.

Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P.

Thromb Res. 2012 Nov;130(5):709-15. doi: 10.1016/j.thromres.2012.07.014. Epub 2012 Aug 2.

PMID:
22857800
14.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

15.

Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study.

Loganathan L, Hua A, Patel S, Gibbons C, Vizcaychipi MP.

Ann R Coll Surg Engl. 2016 Sep;98(7):507-15. doi: 10.1308/rcsann.2016.0197.

PMID:
27580310
16.

Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST, Scott LJ, Plosker GL.

Drugs. 2009;69(13):1829-51. doi: 10.2165/11200890-000000000-00000. Review.

PMID:
19719335
17.

A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.

Turun S, Banghua L, Yuan Y, Zhenhui L, Ying N, Jin C.

Thromb Res. 2011 Jun;127(6):525-34. doi: 10.1016/j.thromres.2011.01.016. Epub 2011 Mar 12. Review.

PMID:
21397931
18.

[Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty].

Miao SG, Zhang XG, Lu JH, Yang Y, Lu N.

Zhongguo Gu Shang. 2015 Oct;28(10):893-6. Chinese.

PMID:
26727779
19.

[Prophylaxis of thrombembolic diseases with rivaroxaban].

Gassanov N, Caglayan E, Erdmann E, Er F.

Dtsch Med Wochenschr. 2010 Nov;135(44):2189-92. doi: 10.1055/s-0030-1267497. Epub 2010 Oct 26. German. No abstract available.

PMID:
20979005
20.

New anticoagulants as thromboprophylaxis after total hip or knee replacement.

Hamidi V, Ringerike T, Hagen G, Reikvam Å, Klemp M.

Int J Technol Assess Health Care. 2013 Jul;29(3):234-43. doi: 10.1017/S0266462313000251. Epub 2013 Jun 17. Review.

PMID:
23768996

Supplemental Content

Support Center